Kura Oncology Profile

19.80
USD 0.1  0.5%
37%
38%

Acquisition by Steven Stein of 13000 shares of Kura Oncology subject to Rule 16b-3

Kura Oncology insider trading alert for grant of option to purchase common stock by Steven Stein, the corporate stakeholder, on June 8, 2018. This event was filed by Kura Oncology Inc with SEC on 2018-06-08. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Kura Oncology Summary

Kura Oncology (KURA) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 34 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 645.06 M. Kura Oncology conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 33.77 M outstanding shares of which 2.33 M shares are now shorted by private and institutional investors with about 5.96 trading days to cover. Kura Oncology currently holds about 125.89 M in cash with (39.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.8.
Check Kura Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 19.8HorizonTargetOdds Above 19.8
37.22%30 days 19.80 62.52%
Based on normal probability distribution, the odds of Kura Oncology to move above current price in 30 days from now is about 62.52% (This Kura Oncology probability density function shows the probability of Kura Oncology Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares2 M36.4 M
Victory Capital Management IncCommon Shares1.5 M27.1 M
View Kura Oncology Diagnostics

Selected Kura Oncology Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Kura Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
7 
Equity ratings for Kura Oncology are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. The company was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 34 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Kura Oncology SEC Filings
Kura Oncology SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameKura Oncology
ChairmanTroy WilsonView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address3033 Science Park Road
ExchangeBATS Exchange
CIK Number0001422143
CUSIP50127T109
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.kuraoncology.com
Phone858 500 8800
CurrencyUSD - US Dollar

Directors

Kura Oncology Corporate Directors
Steven Stein Director
Faheem Hasnain Independent Director
Thomas Malley Director
Please see also Stocks Correlation. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.